Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.

Our results demonstrate that both the quantity of vaccines estimated to be required by the countries considered as well as their ability-to-pay could make a vaccine for leishmaniasis commercially attractive to potential manufacturers. The methodology used can be equally applied to other technology developments targeting health in developing countries.